Targeting SP140 in this paper through silencing in the glioma and ccRCC murine models or GSK761 inhibition provided sentinels for ease of association/reduction, as TRIM22 as well as PI3K/AKT and TLR4-related PD-L1 levels were reduced post-treatment, resulting in reduced tumor invasiveness and re-sensitized T cells [54, 67]. The gene discussed is AKT1; the disease is glioma.